Clinical trials: Mortality
Critical Illness
Does Acetylsalicylic Acid Reduce the Mortality of Patients Admitted to an Intensive Care Unit
Platelets play a central part not just in homeostasis and thrombosis as the primary effector cells, but they are also key cells in the regulation of the immunological response to various stressors.
- Trial name
- NCT02285153
- Testing
- Acetylsalicylic acid lysinate, 0.9% sodium-chloride solution
- Where
- Austria
- Volunteers
- 15 people
- Sponsor
- Medical University of Vienna
Mortality Following Noncardiac Surgery
South African Surgical Outcomes Study
We will conduct a 7 day cohort study of consecutive patients aged 16 years and older undergoing inpatient noncardiac surgery. Patients will be followed up for a maximum of 30 days.
- Trial name
- SASOS (NCT02141867)
- Where
- South Africa
- Volunteers
- 3,927 people
- Sponsor
- University of KwaZulu
Heart Failure With Preserved Ejection Fraction
Efficacy and Safety of LCZ696 Compared to Valsartan, on Morbidity and Mortality in Heart Failure Patients With Preserved Ejection Fraction
The purpose of this study was to evaluate the effect of LCZ696 compared to valsartan in the reduction of cardiovascular death and heart failure(HF) hospitalizations in patients with HF with preserved ejection fraction.
- Trial name
- PARAGON-HF (NCT01920711)
- Testing
- LCZ696, Valsartan
- Where
- 715 sites in United States, Argentina and 41 more
- Volunteers
- 4,822 people
- Sponsor
- Novartis Pharmaceuticals
Pulmonary Arterial Hypertension
Effects of the Combination of Bosentan and Sildenafil Versus Sildenafil Monotherapy on Pulmonary Arterial Hypertension (PAH)
COMPASS-2 is a Phase 4, prospective, randomized, double-blind, placebo-controlled, event-driven study evaluating the effect of bosentan on the time to first confirmed morbidity/mortality event in patients with symptomatic PAH…
- Trial name
- Compass-2 (NCT00303459)
- Testing
- bosentan
- Volunteers
- 334 people
- Sponsor
- Actelion
Bone Marrow Failure Syndromes, Immunodeficiencies
Reduced Intensity Conditioning Using CD3+/CD19+ Depletion for Non Malignant Transplantable Diseases
This is a Phase II trial to determine the ability of a reduced intensity conditioning regimen to allow successful engraftment with CD3+ /CD19+ depleted peripheral stem cell grafts from mismatched donors.
- Conditions
- Bone Marrow Failure Syndromes, Immunodeficiencies, Immune Dysregulation Syndromes
- Trial name
- MiniClini (NCT02277639)
- Testing
- CliniMACs device
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- Children's Hospital of Philadelphia
Obesity
A Long Term Study of Sibutramine and the Role of Obesity Management in Relation to Cardiovascular Disease in Overweight and Obese Patients
The purpose of the study was to determine the long-term effect of sibutramine treatment on cardiovascular outcomes in overweight and obese patients at risk of a cardiovascular event.
- Trial name
- SCOUT (NCT00234832)
- Testing
- Sibutramine hydrochloride
- Where
- United States
- Volunteers
- 10,777 people
- Sponsor
- Abbott
External Causes of Morbidity and Mortality
Post Operative Walking Enhancements for Recovery (POWER) Trial
This study is a non-blinded randomized controlled trial. Consenting participants will be randomized to routine post-operative ambulation vs.
- Trial name
- POWER (NCT01254851)
- Testing
- goal-augmented post-operative care
- Where
- 2 sites in United States
- Volunteers
- 146 people
- Sponsor
- Loyola University
Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia
Safety and Efficacy of Donor T-lymphocytes Depleted ex Vivo of Host Alloreactive T-cells (ATIR) in Patients With a Hematologic Malignancy Who Received a Hematopoietic Stem Cell Transplantation From a Haploidentical Donor
The purpose of this study is to determine whether ATIR is safe and effective in reducing transplant-related mortality and improving overall survival, when infused in patients with a hematologic malignancy following a T-cell…
- Conditions
- Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndrome
- Trial name
- NCT01794299
- Testing
- ATIR
- Where
- 8 sites in Belgium, Canada and 2 more
- Volunteers
- 31 people
- Sponsor
- Kiadis Pharma
Troponin, Age
NIHR CV Health Informatics Collaborative
The National Institute for Health Research (NIHR) Cardiovascular Health Informatics Collaborative is an observational, multi-centre and longitudinal study of clinical data from collaborating hospitals.
- Conditions
- Troponin, Age, Mortality, Acute Coronary Syndrome
- Trial name
- NHIC-CV (NCT03507309)
- Volunteers
- 257,948 people
- Sponsor
- Imperial College London
Acute Biphenotypic Leukemia, Acute Myeloid Leukemia
Liposomal Cytarabine-Daunorubicin CPX-351 in Treating Patients With Untreated Myelodysplastic Syndrome or Acute Myeloid Leukemia
This randomized clinical trial studies liposomal cytarabine-daunorubicin CPX-351 in treating patients with untreated myelodysplastic syndrome or acute myeloid leukemia.
- Conditions
- Acute Biphenotypic Leukemia, Acute Myeloid Leukemia, Myelodysplastic Syndrome, Untreated Adult Acute Myeloid Leukemia
- Trial name
- NCT01804101
- Testing
- Laboratory Biomarker Analysis, Liposomal Cytarabine-Daunorubicin CPX-351
- Where
- 2 sites in United States
- Volunteers
- 48 people
- Sponsor
- Fred Hutchinson Cancer Center
Acute Pulmonary Edema
MIdazolam Versus MOrphine in Acute Pulmonary Edema (MIMO Trial)
Acute pulmonary edema (APE) is a common condition in the emergency room, associated with considerable mortality. The use of intravenous morphine in the treatment of APE remains controversial and Benzodiazepines have been…
- Trial name
- MIMO (NCT02856698)
- Testing
- Midazolam, Morphine
- Where
- 8 sites in Spain
- Volunteers
- 111 people
- Sponsor
- Alberto Dominguez-Rodriguez
Multiple Trauma
Independent Predictors of Mortality in Polytrauma Patients
Prospective observational trial searching for independent predictors of mortality. Data was collected at trauma scene, ER, three and 24 hours of hospital stay.The patients will be followed for 30 days after hospital admission.
- Trial name
- NCT01669577
- Testing
- analysis of blood samples and clinical features
- Where
- Brazil
- Volunteers
- 200 people
- Sponsor
- University of Sao Paulo
Acute Kidney Injury
Epidemiology of Acute Kidney Injury in England - 1998 to 2013
The true population incidence of acute kidney injury (AKI), previously called acute renal failure, in England is not known. A better understanding of the epidemiology of AKI at a national level is essential to inform initiatives…
- Trial name
- NCT02216695
- Where
- United Kingdom
- Volunteers
- 64,882 people
- Sponsor
- University Hospitals of Derby and Burton NHS Foundation Trust
Lymphoid Leukemia, Myeloid Leukemia
Therapeutic Use of Intravenous Vitamin C in Allogeneic Stem Cell Transplant Recipients
This phase 2 trial studies the effect of intravenous (IV) vitamin C repletion after myeloablative allogeneic stem cell transplant.
- Conditions
- Lymphoid Leukemia, Myeloid Leukemia, Monocytic Leukemia, Myelodysplasia
- Trial name
- NCT03613727
- Testing
- Intravenous (IV) and oral Vitamin C
- Where
- United States
- Volunteers
- 61 people
- Sponsor
- Virginia Commonwealth University
Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia
Safety and Efficacy of Two Doses of ATIR101, a T-lymphocyte Enriched Leukocyte Preparation Depleted of Host Alloreactive T-cells, in Patients With a Hematologic Malignancy Who Received a Hematopoietic Stem Cell Transplantation From a Haploidentical Donor
The purpose of this study is to determine whether a repeat dose administration of ATIR101 is safe and effective when infused in patients with a hematologic malignancy following a T-cell depleted stem cell graft from a related…
- Conditions
- Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndrome
- Trial name
- NCT02500550
- Testing
- ATIR101, Haploidentical hematopoietic stem cell transplantation (HSCT), TBI regime
- Where
- 11 sites in Belgium, Canada and 4 more
- Volunteers
- 15 people
- Sponsor
- Kiadis Pharma
Atrial Fibrillation, Atrial Flutter
A Trial With Dronedarone to Prevent Hospitalization or Death in Patients With Atrial Fibrillation
To assess the efficacy of dronedarone in preventing cardiovascular hospitalization or death from any cause in a population of high-risk patients with atrial fibrillation/atrial flutter (AF/AFL).
- Trial name
- ATHENA (NCT00174785)
- Testing
- dronedarone (SR33589)
- Where
- 37 sites in United States, Argentina and 35 more
- Volunteers
- 4,628 people
- Sponsor
- Sanofi